Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
European Heart Journal|February 23, 2019
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trialJonas Oldgren, Philippe Gabriel Steg, Stefan H Hohnloser, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|June 24, 2016
Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohortMenno V Huisman, Chang Sheng Ma, Hans-Christoph Diener, et al.
Journal of Medical Economics|December 17, 2016
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ studyCharles V Pollack, Richard Bernstein, Robert Dubiel, et al.
Circulation|October 15, 2021
Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS TrialMaria Cecilia Bahit, Ralph L Sacco, J Donald Easton, et al.
JACC. Cardiovascular Interventions|December 7, 2019
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial SubanalysisJurrien M Ten Berg, Anne de Veer, Jonas Oldgren, et al.
JACC. Cardiovascular Interventions|April 7, 2021
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI TrialBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.
JACC. Cardiovascular Interventions|August 24, 2019
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCIStefan H Hohnloser, Philippe Gabriel Steg, Jonas Oldgren, et al.
Journal of the American Heart Association|June 3, 2022
Predictors of Recurrent Stroke After Embolic Stroke of Undetermined Source in the RE-SPECT ESUS TrialVictor J Del Brutto, Han-Christoph Diener, J Donald Easton, et al.
The New England Journal of Medicine|August 29, 2017
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial FibrillationChristopher P Cannon, Deepak L Bhatt, Jonas Oldgren, et al.
The American Journal of Medicine|May 12, 2020
Comparison of Dabigatran Plus a P2Y<sub>12</sub> Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCIRaffaele De Caterina, Antonio Procopio, José-Luis Lopez Sendon, et al.
Pageof 3